We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Suit Targets Impax’s Move To Sell Generic Amrix

Law360 (January 8, 2009, 12:00 AM EST) -- Impax Laboratories Inc. said Thursday it has been tied into a patent infringement suit over its plans to market a generic Amrix, a skeletal muscle relaxant produced by Pennsylvania-based Cephalon Inc.

Cephalon lodged the suit in the U.S. District Court for the District of Delaware after the Hayward, Calif.-based specialty pharmaceutical firm submitted an abbreviated new drug application for cyclobenzaprine hydrochloride extended release capsules to the U.S. Food and Drug Administration, according to Impax.

Impax’s ANDA includes a Paragraph IV certification, which asserts the generic version...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.